Article

Advancing Liver Cancer Precision Medicine with TARGET-SL

2026-05-21

Abstract excerpt

<h4>Background and Aims</h4> A major goal of personalised liver oncology is the ability to make targeted predictions about cancer-specific toxicity, however there are limited methods available. To address this, we validated the performance of our bioinformatics framework, TARGET-SL, through ex vivo drug screening. <h4>Methods</h4> Using TARGET-SL we predicted gain of function (GOF), loss of function (LOF) and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 924826b1-9282-5b6d-9da3-5704c6fbee87
DOI: 10.64898/2026.05.19.725819

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Advancing Liver Cancer Precision Medicine with TARGET-SLDOI 10.64898/2026.05.19.725819Read

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsSemantic proximity Read

Leveraging Patient-Derived Organoids for Personalized Liver Cancer Treatment.Semantic proximity Read

Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancerSemantic proximity Read

Mapping the landscape of synthetic lethal interactions in liver cancerSemantic proximity Read

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.Semantic proximity Read

Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneitySemantic proximity Read

Human-correlated genetic HCC models identify combination therapy for precision medicineSemantic proximity Read

Higher order synthetic lethals are keys to minimize cancer treatment effects on non-tumor cellsSemantic proximity Read

Genome sequencing analysis of liver cancer for precision medicine.Semantic proximity Read

Development of a system combining comprehensive genotyping and organoid cultures for identifying and testing genotype-oriented personalised medicine for pancreatobiliary cancers.Semantic proximity Read

Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time.Semantic proximity Read

Integrated characterization of hepatobiliary tumor organoids provides a potential landscape of pharmacogenomic interactionsSemantic proximity Read